Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Lymphoma, Mantle- Cell
Interventions: Everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 31
States / cities: Multiple Locations, Arizona • Fayetteville, Arkansas • Concord, California + 25 more

Conditions: Chronic Periodontitis
Interventions: Scaling and root planing, Scaling and root planing with solution; Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 30 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Retinoblastoma
Interventions: Episcleral Topotecan; Drug
Lead sponsor: Targeted Therapy Technologies, LLC; Industry
Eligibility: Up to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Advanced Solid Cancer, Metastatic Solid Cancer
Interventions: BI 3819026, Ezabenlimab (BI 754091); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: New Haven, Connecticut • Hackensack, New Jersey • New York, New York + 1 more

Conditions: Hypertriglyceridemia
Interventions: REGN1500, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Healthy Volunteers
Interventions: Decitabine-THU; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, Placebo, RO5190591 (Danoprevir); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more

Conditions: Colorectal Cancer
Interventions: Fruquintinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more

Conditions: Hyperparathyroidism
Interventions: Parathyroid Surgery, Telephone Interview, Polysomnography (PSG); Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus
Interventions: Well-controlled diabetic (WC), Poorly controlled diabetics (PC); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Houston, Texas • Seattle, Washington

Conditions: Hiv, HIV/AIDS, HIV Infections, AIDS, AIDS and Infections, Aids/Hiv Problem
Interventions: N-803 and bNAbs, haNK™ Cells; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Total Occlusion of Arteries of the Extremities
Interventions: SoundBite™ Crossing System - Peripheral; Device
Lead sponsor: SoundBite Medical Solutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Healthy Participants
Interventions: UCB9741, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Subjects (HS)
Interventions: TNX-102 SL; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pregnancy Related
Interventions: Video Counseling; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Efavirenz, Metabolism and Pharmacokinetics Changes
Interventions: Efavirenz, voriconazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Rheumatoid Arthritis
Interventions: ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: El Cajon, California • Encino, California • La Jolla, California + 8 more

Conditions: Coffee, Anthocyanins, Exercise Performance
Interventions: Ethiopian Coffee, Supplement, Water (Placebo); Other · Dietary Supplement
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions: RVU120(SEL120); Drug
Lead sponsor: Ryvu Therapeutics SA; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more

Conditions: Obesity
Interventions: Sequential BT, Standard BT; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions: Budesonide, Saline alone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Weight Bias, Health Professions Education, Implicit Bias
Interventions: Exercise with Obesity Simulation Suit, Exercise-only, Control; Behavioral
Lead sponsor: University of Wisconsin, River Falls; Other
Eligibility: 18 Years to 30 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: River Falls, Wisconsin

Conditions: Sebaceous Hyperplasia, Skin Abnormalities, Skin Lesion
Interventions: Nano-Pulse Stimulation (NPS); Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 3 more

Search by objective public record fields.

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

Effect of Disinfective Solution as an Adjunct to Maintenance Therapy of Inflamed Periodontal Pockets

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Effect of Parathyroidectomy on Sleep

Alveolar Bone Changes in Diabetes (ABCD) Study

N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV

Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in HF Patients (CONFIRM-HF)

SoundBite™ Crossing System Pivotal Peripheral CTO Crossing Study

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects

Video Counseling: A Randomized Control Trial

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

Exercise-Based Obesity Simulation and Weight Bias

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study